These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 15818146)

  • 1. Cholestasis and cholestatic syndromes.
    Pratt DS
    Curr Opin Gastroenterol; 2005 May; 21(3):270-4. PubMed ID: 15818146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholestasis and cholestatic syndromes.
    Rutherford AE; Pratt DS
    Curr Opin Gastroenterol; 2006 May; 22(3):209-14. PubMed ID: 16550034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholestasis and cholestatic syndromes.
    O'Leary JG; Pratt DS
    Curr Opin Gastroenterol; 2007 May; 23(3):232-6. PubMed ID: 17414837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Autotaxin Activity Correlates With Pruritus in Pediatric Cholestatic Disorders.
    Kremer AE; Gonzales E; Schaap FG; Oude Elferink RP; Jacquemin E; Beuers U
    J Pediatr Gastroenterol Nutr; 2016 Apr; 62(4):530-5. PubMed ID: 26628447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
    Trauner M; Fickert P; Halilbasic E; Moustafa T
    Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical causes of cholestasis.
    Nguyen KD; Sundaram V; Ayoub WS
    World J Gastroenterol; 2014 Jul; 20(28):9418-26. PubMed ID: 25071336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
    Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
    Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholestatic syndromes.
    Trauner M; Boyer JL
    Curr Opin Gastroenterol; 2004 May; 20(3):220-30. PubMed ID: 15703646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of cholestasis.
    Zollner G; Trauner M
    Clin Liver Dis; 2008 Feb; 12(1):1-26, vii. PubMed ID: 18242495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System.
    Nakanishi Y; Saxena R
    Arch Pathol Lab Med; 2015 Jul; 139(7):858-66. PubMed ID: 26125426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ascending pathophysiology of cholestatic liver disease.
    Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
    Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary biliary cirrhosis and primary sclerosing cholangitis.
    Angulo P; Lindor KD
    Clin Liver Dis; 1999 Aug; 3(3):529-70. PubMed ID: 11291238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular transporters and cholestasis.
    Pauli-Magnus C; Meier PJ
    J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S103-10. PubMed ID: 15758645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of cholestasis.
    Kullak-Ublick GA; Meier PJ
    Clin Liver Dis; 2000 May; 4(2):357-85. PubMed ID: 11232196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders.
    Vleggaar FP; Van Ooteghem NA; Van Buuren HR; Van Berge Henegouwen GP
    Scand J Gastroenterol Suppl; 2000; (232):86-92. PubMed ID: 11232499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rodent models of cholestatic liver disease: A practical guide for translational research.
    Gijbels E; Pieters A; De Muynck K; Vinken M; Devisscher L
    Liver Int; 2021 Apr; 41(4):656-682. PubMed ID: 33486884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
    Trauner M; Wagner M; Fickert P; Zollner G
    J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
    Stiehl A; Rudolph G; Sauer P; Theilmann L
    J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholestatic liver diseases: new strategies for prevention and treatment of hepatobiliary and cholestatic diseases.
    van de Meeberg PC; Wolfhagen FH; van Erpecum KJ; van Berge Henegouwen GP
    Neth J Med; 1995 Jul; 47(1):30-5. PubMed ID: 7651564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.